AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Exagen Inc.
Video analysis: XGN
All videosNo video analysis for this stock yet. Request one from our team.
News: XGN
Exagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation
Reviewing Amplifon (OTCMKTS:AMFPF) & Exagen (NASDAQ:XGN)
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Analyst Ratings This is a breakdown of current ratings and
Exagen Q2 Earnings Call Highlights
Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
Exagen Inc. Reports Second Quarter 2026 Financial Results
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.
Exagen Inc. to Participate in Upcoming Investor Conference
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference – Boston, MA Date: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen's Investor Relations website at investors.exagen.com.
Exagen to Announce Second Quarter Financial Results on August 4, 2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.
